Sin J I, Sung J H, Suh Y S, Lee A H, Chung J H, Sung Y C
Department of Life Science, School of Environmental Engineering, Pohang University of Science and Technology, Kyung-buk, Korea.
Vaccine. 1997 Dec;15(17-18):1827-33. doi: 10.1016/s0264-410x(97)88856-1.
For DNA vaccination studies, recombinant VP1 protein of encephalomyocarditis virus (EMCV) was produced from Escherichia coli, and eukaryotic VP1 expression vector, pCT-Gs-VP1, was generated and used as a DNA vaccine. Mice were immunized intramuscularly (i.m.) with pCT-Gs-VP1 in the presence or absence of plasmid DNA expressing granulocyte-macrophage colony stimulating factor (GM-CSF), and were subsequently analyzed for their anti-VP1 immune responses with recombinant VP1 in ELISA. Immunization of mice with pCT-Gs-VP1 resulted in VP1-specific immune response and 43% protection from subsequent lethal heterologous challenge of EMCV. Coinjection of mice with pCT-Gs-VP1 and plasmid DNA encoding GM-CSF was shown to increase the seroconversion rate of the immunized mice with a single DNA injection, and enhanced to a higher degree VP1-specific immunity, which appeared to result in better protection (about 80%) from lethal virus challenge. Thus, our results provide evidence for the potential use of GM-CSF to induce better immune response and resistance against viral infection in DNA vaccination.
在DNA疫苗接种研究中，脑心肌炎病毒（EMCV）的重组VP1蛋白由大肠杆菌产生，真核VP1表达载体pCT-Gs-VP1构建成功并用作DNA疫苗。在有或没有表达粒细胞-巨噬细胞集落刺激因子（GM-CSF）的质粒DNA存在的情况下，用pCT-Gs-VP1对小鼠进行肌肉注射免疫，随后用重组VP1通过ELISA分析其抗VP1免疫反应。用pCT-Gs-VP1免疫小鼠产生了VP1特异性免疫反应，并对随后的EMCV致死性异源攻击提供了43%的保护。结果表明，将pCT-Gs-VP1与编码GM-CSF的质粒DNA共同注射给小鼠，单次DNA注射可提高免疫小鼠的血清转化率，并在更高程度上增强VP1特异性免疫，这似乎能提供更好的保护（约80%）以抵抗致死性病毒攻击。因此，我们的结果为GM-CSF在DNA疫苗接种中诱导更好的免疫反应和抗病毒感染抵抗力的潜在用途提供了证据。
